Carfilzomib公司
来那度胺
多发性骨髓瘤
地塞米松
硼替佐米
医学
肿瘤科
内科学
荟萃分析
作者
Bruno Almeida Costa,Thomaz Alexandre Costa,Kevin Pak,Aesha Patel,Nicole Félix,Tarek H. Mouhieddine,Joshua Richter
摘要
Graphical Abstract In view of the increasing data evaluating carfilzomib-based induction for newly-diagnosed multiple myeloma (NDMM), we conducted a systematic review and meta-analysis comparing the efficacy of carfilzomib/lenalidomide/dexamethasone (KRd) versus bortezomib/lenalidomide/dexamethasone (VRd). Three studies totaling 1597 patients (50% KRd-treated, 50% VRd-treated) were included. Despite similar survival outcomes and overall response rate compared with the VRd arm, KRd-treated subjects showed higher odds of achieving complete responses and measurable residual disease negativity. Among patients with high-risk cytogenetics (n = 348), KRd was associated with significant improvement in progression-free survival (HR = 0.70; 95% CI = 0.50–0.97; p = .03; I2 = 0%), suggesting carfilzomib-based induction may be preferable in this NDMM subpopulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI